The safety and tolerability of ZORYVE foam 0.3% were previously confirmed in the STRATUM Phase 3 study. Additionally, ZORYVE cream 0.05% was well tolerated, with no or minimal irritation at the application site, including after the first application. Recently, both ZORYVE cream 0.3% and ZORYVE foam 0.3% were awarded the National Psoriasis Foundation’s Seal of Recognition—the first FDA-approved product to receive the honor. The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%). Please see full Prescribing Information for ZORYVE cream and full Prescribing Information for ZORYVE foam.